We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
Clinical evaluation of sulbactam/ampicillin in Japan.
A total of 754 patients were treated intravenously with sulbactam/ampicillin, in a clinical trial to determine the efficacy and safety of the drug. The majority of patients were treated with 3 g/day by intravenous infusion for 4 to 14 days. Clinical response was evaluated in 689 of 754 patients. In the treatment of respiratory and urinary tract infections, efficacy was 82.5% and 77.1%, respectively. Overall, sulbactam/ampicillin was effective in 80.4% of all evaluable patients. Of 175 patients who failed to respond to prior antibiotic therapy, 135 patients (77.1%) were effectively treated with sulbactam/ampicillin. The overall bacteriological eradication rate was 91.8% against Gram-positive organisms, 75.9% against Gram-negative organisms, and 90% against anaerobes. In addition, 166 of 221 strains that were beta-lactamase producers were eradicated after treatment with sulbactam/ampicillin. Side effects such as rash, fever, itching, urticaria, and diarrhea occurred in only 2.65%, 20 of 754 cases. Laboratory abnormalities were similar to those reported for other beta-lactam antibiotics, including increases in levels of SGOT (4.9%), SGPT (5.7%), and eosinophilia (3.4%) counts. The study showed that sulbactam/ampicillin has a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative organisms as well as anaerobes. There was a high degree of safety. Thus, sulbactam/ampicillin is effective and safe as a treatment for medical, surgical, urological, and gynecological infections.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app